| The incidence, risk factors, and outcomes with 5-fluorouracil–associated coronary vasospasm A Zafar, ZD Drobni, R Mosarla, RM Alvi, M Lei, UY Lou, VK Raghu, ... Cardio Oncology 3 (1), 101-109, 2021 | 51 | 2021 |
| Current treatment strategies for multiple myeloma A Branagan, M Lei, U Lou, N Raje JCO oncology practice 16 (1), 5-14, 2020 | 47 | 2020 |
| CAR T-cell-associated neurotoxicity: current management and emerging treatment strategies AM Rivera, S May, M Lei, S Qualls, K Bushey, DB Rubin, ME Barra Critical care nursing quarterly 43 (2), 191-204, 2020 | 42 | 2020 |
| Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study JE Haydu, JS Maron, RA Redd, KME Gallagher, S Fischinger, JA Barnes, ... Blood advances 6 (6), 1671-1683, 2022 | 20 | 2022 |
| Evaluation of the impact of thyroiditis development in patients receiving immunotherapy with programmed cell death-1 inhibitors M Lei, A Michael, S Patel, D Wang Journal of Oncology Pharmacy Practice 25 (6), 1402-1411, 2019 | 17 | 2019 |
| Safety and efficacy of a urine alkalinization protocol developed for high-dose methotrexate patients during intravenous bicarbonate shortage AM Roy, M Lei, U Lou Journal of Oncology Pharmacy Practice 25 (8), 1860-1866, 2019 | 16 | 2019 |
| Current management and emerging treatment strategies for multiple myeloma M Lei, EB Kim, A Branagan, U Lou, M Zemel, N Raje Rinsho Ketsueki 60 (9), 1243-1256, 2019 | 16 | 2019 |
| The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm A Zafar, ZD Drobni, M Lei, CA Gongora, T Quinaglia, UY Lou, R Mosarla, ... PLoS One 17 (4), e0265767, 2022 | 14 | 2022 |
| Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma JD Soumerai, A Rosenthal, S Harkins, J Duffy, C Mecca, Y Wang, ... Blood, The Journal of the American Society of Hematology 140 (16), 1822-1826, 2022 | 9 | 2022 |
| Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma MM Lei, E Tavares, E Buzgo, U Lou, N Raje, AJ Yee Leukemia & Lymphoma 63 (13), 3249-3252, 2022 | 6 | 2022 |
| Incidence of invasive fungal infections in acute myeloid leukemia without antifungal prophylaxis J Signorelli, M Lei, J Lam, M Jalbut, PC Amrein, AT Fathi, G Hobbs, ... Clinical Lymphoma Myeloma and Leukemia 20 (11), e883-e889, 2020 | 5 | 2020 |
| Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma MM Lei, MN Sorial, U Lou, M Yu, A Medrano, J Ford, RA Nemec, ... Leukemia & Lymphoma 65 (5), 653-659, 2024 | 4 | 2024 |
| Combined analysis of the impact of second-generation BTK inhibitors on patient outcomes RA Redd, J Ford, M Lei, JS Abramson, JD Soumerai Leukemia & Lymphoma 64 (14), 2296-2305, 2023 | 4 | 2023 |
| Clinical application of genomics in Waldenström macroglobulinemia AR Branagan, M Lei, SP Treon, JJ Castillo Leukemia & Lymphoma 62 (8), 1805-1815, 2021 | 4 | 2021 |
| Evaluating the incidence of chemotherapy-induced nausea and vomiting in patients with B-cell lymphoma receiving dose-adjusted EPOCH and rituximab E Uchida, MM Lei, E Roeland, U Lou Journal of Oncology Pharmacy Practice 28 (1), 119-126, 2022 | 3 | 2022 |
| Letermovir and tacrolimus interaction effects in hematopoietic cell transplantation recipients receiving moderate cytochrome P450 3A4 inhibitors for antifungal prophylaxis J Malespini, M Lei, E Tavares, SP Hammond, YB Chen, SO Luk, ... Journal of Oncology Pharmacy Practice 29 (7), 1574-1579, 2023 | 2 | 2023 |
| COVID-19 vaccine responsiveness in patients with multiple myeloma and Waldenström macroglobulinemia AR Branagan, MM Lei, JS Maron, AJ Yee, E O'Donnell, JJ Castillo, ... Blood 138, 3801, 2021 | 2 | 2021 |
| Impact of therapy sequence on survival outcomes among patients with relapsed or refractory mature T and NK cell neoplasms: a global retrospective cohort study MN Sorial, MJ Koh, L Boussi, JX Han, L Peng, IJ Eche-Ugwu, R Duan, ... Blood 142, 3080, 2023 | 1 | 2023 |
| Practice Efficiency Associated with Epcoritamab for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma from an Institutional Perspective MM Lei, Q Li, K O'Day, K Meyer, A Wang, M Jun Blood 142, 7254, 2023 | 1 | 2023 |
| Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia AR Branagan, MM Lei, CC Mo, AJ Yee, EK O'Donnell, JJ Castillo, ... Blood 140 (Supplement 1), 10094-10096, 2022 | 1 | 2022 |
Andrew R Branagan, MD, PhDMassachusetts General Hospital, Harvard Medical SchoolVerified email at mgh.harvard.edu
